AGILE 3+评分用于诊断非酒精性脂肪性肝病进展性纤维化及预测肝脏相关事件
本研究纳入614例经活检证实或临床诊断的NAFLD相关代偿期肝硬化患者,评估AGILE 3+评分相较FIB-4和瞬时弹性成像LSM对进展性纤维化的诊断准确性及对肝脏相关事件(LREs)的预测能力。在520例活检证实的NAFLD患者中,LSM和AGILE 3+诊断进展性纤维化的AUROC均高于FIB-4(0.88 vs 0.78,P<.001),AGILE 3+的不确定区域更小(8.3%,FIB-4为25.2%,LSM为13.1%)。在全队列中,AGILE 3+预测36、60、96个月LRE的AUROC均显著高于LSM。
要点
- AGILE 3+诊断进展性纤维化的AUROC为0.88,高于FIB-4的0.78(P<.001)。
- AGILE 3+的不确定区域为8.3%,小于FIB-4的25.2%和LSM的13.1%。
- AGILE 3+预测LRE的AUROC在36、60、96个月均显著高于LSM(P=.008、.006、.001)。
核心结论
- 根据资源可及性、临床场景和风险情况,AGILE 3+是FIB-4和LSM之外用于NAFLD患者无创评估疾病严重程度和预后的准确且有效的替代方法。
研究设计与样本
- 共纳入614例经活检证实NAFLD或临床诊断为NAFLD相关代偿期肝硬化的连续患者,随访记录肝脏相关事件(LREs)。
- 测量FIB-4、瞬时弹性成像(FibroScan设备)LSM和AGILE 3+,采用AUROC和决策曲线分析评估诊断和预测性能。
主要发现
- 在520例经活检证实的NAFLD患者中,LSM和AGILE 3+诊断进展性纤维化的AUROC均为0.88,FIB-4为0.78(P<.001)。
- 不确定区域:FIB-4为25.2%,LSM为13.1%,AGILE 3+为8.3%。
- 在全队列中,AGILE 3+预测LRE的AUROC在36个月为0.95 vs LSM 0.93(P=.008),60个月为0.95 vs 0.92(P=.006),96个月为0.97 vs 0.95(P=.001)。
- 决策曲线分析显示,在进展性纤维化不存在时,所有评分在5%至10%风险阈值下排除进展性纤维化的净获益有限。
- 在36、60、96和120个月LRE的5%假阴性或假阳性风险阈值下,AGILE 3+排除LRE均优于FIB-4和LSM。
临床怎么用
- 原文结论指出,根据资源可及性、临床场景和风险情况,AGILE 3+可作为FIB-4和LSM的准确且有效的替代方法用于NAFLD无创评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We aimed to assess the diagnostic accuracy of AGILE 3+, a recently developed score based on the combination of aspartate aminotransferase/alanine aminotransferase ratio, platelet count, diabetes status, sex, age, and liver stiffness measurement (LSM) by transient elastography, when compared with Fibrosis-4 (FIB-4) and LSM, for the diagnosis of advanced fibrosis and for the prediction of liver-related events (LREs) occurrence in patients with NAFLD. METHODS: A total of 614 consecutive patients with biopsy-proven NAFLD or clinical diagnosis of NAFLD-related compensated cirrhosis were enrolled. LREs were recorded during follow-up. FIB-4, LSM by transient elastography (FibroScan device), and AGILE 3+ were measured. The diagnostic performance of noninvasive criteria for advanced fibrosis and for the prediction of LREs was assessed using the area under the receiver operating characteristic curve (AUROC) and decision curve analysis. RESULTS: In patients with biopsy-proven NAFLD (n = 520), LSM and AGILE 3+ had higher AUROC than FIB-4 (0.88 for LSM and AGILE 3+ vs 0.78 for FIB-4; P < .001) for advanced fibrosis, and AGILE 3+ exhibited a smaller indeterminate area in the test (25.2% for FIB-4 vs 13.1% for LSM vs 8.3% for AGILE 3+). Within the entire cohort of patients, AGILE 3+ had significantly higher AUROC for predicting LREs with respect to LSM (AUROC 36 months 0.95 vs 0.93; P =.008; 60 months 0.95 vs 0.92; P = .006; 96 months 0.97 vs 0.95; P = .001). Decision curve analysis showed that all scores had modest net benefit for ruling-out advanced fibrosis at the risk threshold of 5% to 10% where advanced fibrosis was absent. At the risk threshold of 5% of false negatives or false positives in LRE at 36, 60, 96, and 120 months, AGILE 3+ outperformed both FIB-4 and LSM for ruling out LRE. CONCLUSIONS: Depending on resource availability, clinical setting, and the risk scenarios, AGILE 3+ is an accurate and valid alternative to FIB-4 and LSM for the noninvasive assessment of disease severity and prognosis in patients with NAFLD.
引用
- Pennisi G, Enea M, Pandolfo A, et al. AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD. Clin Gastroenterol Hepatol. 2022. PMID: 35842119. doi:10.1016/j.cgh.2022.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。